Skip to content

Treatment of chronic knee osteoarthritis with PRP with reduced Leukocyte content

The effects of PRP with reduced Leukocyte content therapy on chronic knee osteoarthritis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160422027520N14
Enrollment
15
Registered
2019-08-24
Start date
2019-08-23
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis. Erosive (osteo)arthritis

Interventions

Intervention 1: Intervention group: In this group of patients, 10 ml of blood will be taken by PRP-specific syringe manufactured by Pishtaz Teb Zaman CO. and according to kit protocol, we will separat

Sponsors

Pishtaz Teb Zaman CO.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Men and women between the ages of 18 and 75 with OA diagnosis based on the American College of Rheumatology Analog scale of knee pain (VAS) equal to or greater than 2.5 People with at least 4 months of history of pain or swelling in one or both knees Radiological classification scale Kellgren-Lawrence 1 or 2 The availability of individual during the study period BMI Between 20 and 35

Exclusion criteria

Exclusion criteria: People under the age of 18 and over 75 years Pregnant women or women who are breastfeeding People with malignancy,People with severe heart disease, uncontrolled diabetes mellitus, rheumatoid arthritis, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome People with acetaminophen or vicodin addiction or a history of drug misuse History of cortisone injections in the last 6 weeks The use of non-steroidal anti-inflammatory drugs 1 week ago Having hemoglobin less than 11 g / dl and platelet count less than 150000 / mµ The use of inhibitors of platelet aggregation and anti-coagulation such as heparin History of knee surgery in the last 3 months Extraordinary deformation (varus >5?, valgus >5?)

Design outcomes

Primary

MeasureTime frame
Determining knee pain. Timepoint: Before injection and 1, 3 and 6 months after the first injection. Method of measurement: Questionnaire (VAS).;Determination of knee function. Timepoint: Before injection and 1, 3 and 6 months after the first injection. Method of measurement: Questionnaire (WOMAC), Questionnaire (KOOS).;Determine the range of knee motion. Timepoint: Before injection and 1, 3 and 6 months after the first injection. Method of measurement: Manual joiniometry.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Yousefi

Tabriz University of Medical Sciences

yousefime@tbzmed.ac.ir+98 41 3336 4665

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026